TriangleNCT01175980 · REGISTRY CONDITION SEARCH
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2020-08-03
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Objective Response According to RECIST 1.1 Criteria
Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0
Time to Recurrence (TTR)
Response Duration (RD)
Progression-free Survival (PFS)
Overall Survival (OS)
Metabolic Response by PET/CT Scan
Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks
Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue
Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue
Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population.
The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample
Stable Disease Duration (SDD)
Expression Level of HR23B
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients must have histologically or cytologically confirmed locally advanced, recurrent or metastatic adenoid cystic carcinoma * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm by chest x-ray, as \>= 10 mm with CT scan, or \>= 10 mm with calipers by clinical exam; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters) * Patients must have locally advanced and/or recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy; any prior number of chemotherapy regimens is allowed; a minimum of at least 4 weeks since prior chemotherapy or radiation therapy should have elapsed, 6 weeks if the last regimen included carmustine (BCNU) or mitomycin C * Life expectancy of greater than 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits (WNL) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal (ULN) * Creatinine within normal institutional limits or * Creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of vorinostat will be determined following review of their case by the principal investigator * No other diagnosis of malignancy unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed \>= 5 years previously and currently with no evidence of disease; however - if the patient has had a previously diagnosed stage I/II malignancy of another type, consideration for recruitment may be made by the Cancer Therapy Evaluation Program (CTEP) senior investigator after discussion with local principal investigator (PI) and patient's physician * Confirmed availability of tumor tissue (either fresh or from paraffin block) from the primary tumor or metastatic site to be available to use on correlative studies * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document * If the patient's tumor can be easily accessed, a pre-treatment biopsy will be mandatory Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; more than 21 days from major surgery should have elapsed before the first dose of the study drug * Patients may not be receiving any other investigational agents or have received vorinostat in the past; patients should not have taken valproic acid for at least 4 weeks prior to enrollment * Inability to take oral medications on a continuous basis * Patients with active brain metastases should be excluded from this clinical trial; patients with previous brain metastases will be eligible if condition is treated and stable for \>= 1 month * History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat * Patient is unable or unwilling to abide by the study protocol and to cooperate fully with the investigator or designee * Patient on current therapy with enzyme-inducing anticonvulsants
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Other: Laboratory Biomarker Analysis
- Drug: Vorinostat
- label
- Treatment (vorinostat)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Treatment (vorinostat)
- description
- Correlative studies
- name
- Laboratory Biomarker Analysis
- type
- OTHER
- arm Group Labels
- Treatment (vorinostat)
- description
- Given PO
- name
- Vorinostat
- other Names
- L-001079038
- MSK-390
- SAHA
- Suberanilohydroxamic Acid
- Suberoylanilide Hydroxamic Acid
- Zolinza
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 30
- type
- ACTUAL
Registered outcome plans (not posted results)
- other Outcomes
- description
- Will assess the association between a metabolic response by PET/CT after one course of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria. Will also assess the association between a metabolic response by PET/CT after the first and second chemotherapy courses and PFS.
- measure
- Metabolic Response by PET/CT Scan
- time Frame
- Up to 56 days
- description
- Number of patients with Flow sort diploid populations of tumor cells from FFPE tissue blocks reported as a count of participants.
- measure
- Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Number of patients with Flow sort aneuploid populations of tumor cells from FFPE tissue. Reported as descriptive results.
- measure
- Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Number of patients with Flow sort tetraploid populations of tumor cells from FFPE tissue. Reported as descriptive results.
- measure
- Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Genomic profile of each cell population using oligonucleotide CGH arrays. Reported as unique probes on the CGH array.
- measure
- Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population.
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets.
- measure
- The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate.
- measure
- Stable Disease Duration (SDD)
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Exact logistic modeling investigation would yield a point and 90% CI estimate of the odds ratio for response.
- measure
- Expression Level of HR23B
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- primary Outcomes
- description
- Objective (Best) response according to RECIST 1.1 criteria.
- measure
- Objective Response According to RECIST 1.1 Criteria
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- secondary Outcomes
- description
- Toxicity will be tabulated via frequency distributions, and also dichotomized to report the proportion (and percentage) of patients experiencing a specified level (e.g., grade 3-4) of toxicity.
- measure
- Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0
- time Frame
- Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- TTR will be summarized descriptively, reporting N, median, mean, standard deviation, standard error (SE), minimum, maximum, and 90% CI for the mean calculated from the SE and asymptotic normal distribution theory.
- measure
- Time to Recurrence (TTR)
- time Frame
- From the start of the treatment until the RECIST measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded, assessed up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Median point estimate and full range will be documented, since only two patients achieved a response.
- measure
- Response Duration (RD)
- time Frame
- From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months
- description
- Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both median point estimate and 90% confidence interval (CI) estimate.
- measure
- Progression-free Survival (PFS)
- time Frame
- From start of treatment to time of progression or death, whichever occurs first, assessed up to 60 months after the last dose of vorinostat maximum treatment duration= 24 months
- description
- Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both point and 90% CI estimates of various statistics of interest can be calculated (e.g., median, 6-month event-free rate, 12-month event-free rate, etc.). Statistical graphs of each K-M curve (with 90% CI lines) will be generated for visual display. (One year survival rate will be given since OS median was not reached due to too few events)
- measure
- Overall Survival (OS)
- time Frame
- From the start of treatment until death from any cause, duration for reported probability= 1 year; survival data collected for up to a total of 60 months
Full study description
- brief Summary
- This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- detailed Description
- PRIMARY OBJECTIVES: I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). SECONDARY OBJECTIVES: I. To characterize the safety and tolerability of vorinostat in this patient population. II. To assess the time to tumor response (TTR). III. To assess the response duration (RD). IV. To evaluate progression free survival (PFS). V. To assess overall survival (OS). TERTIARY OBJECTIVES: I. To assess the association between a metabolic response by positron emission tomography (PET)/computed tomography (CT) after one cycle of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria (RECIST). II. To assess the association between a metabolic response by PET/CT after the first and second chemotherapy cycle and PFS. III. To assess flow sort diploid, aneuploid, and tetraploid populations of tumor cells from formalin fixed, paraffin-embedded (FFPE) tissue blocks from patients who benefited from suberoylanilide hydroxamic acid (SAHA) therapy and from patients who did not demonstrate a durable benefit. IV. Profile the genomes of each cell population using oligonucleotide comparative genomic hybridization (CGH) arrays. V. Perform whole exome analysis of the sorted tumor population and matching germ line sample for each of the patients selected. VI. To assess stable disease duration (SDD). VII. To assess the association between response to vorinostat treatment and RAD23 homolog B (HR23B) on tumor paraffin blocks. VIII. Retrospectively compare volumetric density (viable tumor volume = VTV) with pre-determined RECIST of target lesions in cross sectioning imaging (CT/magnetic resonance \[MR\]) already obtained. IX. Correlate VTV, RECIST and treatment response (partial response, stable disease, progressive disease and stable disease over 6 months). OUTLINE: Patients receive vorinostat orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up for 180 days.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-eb9b4ae7db99f62687e0
- requested nct id
- NCT01175980
- primary nct id
- NCT01175980
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
- payload sha256
- b5ba53500b8a0b6acfc3342c370d8d8aad963794d9294dcec6caaa7878b6da82
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-eb9b4ae7db99f62687e0
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01175980
- occurrences
- context exact
- NCT01175980
- end
- 11
- exact text
- NCT01175980
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Salivary Gland Cancer
- query disease state id
- ds-salivary-gland-cancer
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
- source file sha256
- 38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
- source json pointer
- /studies/26/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c17a575ad9af1d493b7944a8b9e63c428d344e79163d55d32bda6327745630e7
Preserved source evidence · Not medical advice